VivoSim Labs, Inc. Restructuring Costs
VivoSim Labs, Inc. (VIVS) reported Restructuring Costs of $2.10 million for the 12-month period ending 2015-03-31, per its 10-K filed 2015-06-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2015-06-09
- VivoSim Labs, Inc. restructuring costs for the quarter ending 2014-03-31 was $0.00, a 100.00% decline year-over-year.
- VivoSim Labs, Inc. restructuring costs for the quarter ending 2013-12-31 was $0.00.
- VivoSim Labs, Inc. restructuring costs for the quarter ending 2013-09-30 was $0.00.
- VivoSim Labs, Inc. restructuring costs for the quarter ending 2013-06-30 was $2.10M.
- VivoSim Labs, Inc. restructuring costs for fiscal 2015 was $2.10M, a 0.00% change from fiscal 2014.
- VivoSim Labs, Inc. restructuring costs for fiscal 2014 was $2.10M.
- VivoSim Labs, Inc. restructuring costs for fiscal 2012 was $2.10M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2015-03-31 | $2.10M 10-K · filed 2015-06-09 | |||
| 2014-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-06-10 | $0.00 derived: sum of 2 quarters · filed 2014-06-10 | $0.00 derived: sum of 3 quarters · filed 2014-06-10 | $2.10M 10-K · filed 2014-06-10 |
| 2013-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-02-06 | $0.00 derived: sum of 2 quarters · filed 2014-02-06 | $2.10M 10-Q · filed 2014-02-06 | $4.20M derived: sum of 4 quarters · filed 2014-02-06 |
| 2013-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-11-08 | $2.10M 10-Q · filed 2013-11-08 | $4.20M derived: sum of 3 quarters · filed 2013-11-08 | $4.17M derived: sum of 4 quarters · filed 2013-11-08 |
| 2013-06-30 | $2.10M 10-Q · filed 2013-08-09 | $4.20M derived: sum of 2 quarters · filed 2013-08-09 | $4.17M derived: sum of 3 quarters · filed 2013-08-09 | $4.17M derived: sum of 4 quarters · filed 2013-08-09 |
| 2013-03-31 | $2.10M 10-KT · filed 2013-05-24 | $2.07M derived: sum of 2 quarters · filed 2013-05-24 | $2.07M derived: sum of 3 quarters · filed 2013-05-24 | |
| 2012-12-31 | -$29.50K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | -$29.50K derived: sum of 2 quarters · filed 2013-03-15 | $2.10M 10-K · filed 2013-03-15 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $2.13M 10-Q · filed 2012-11-14 | ||
| 2012-06-30 | $2.13M 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |